Device Trial Radar · NCT07178951
Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Sep 9, 2026
Primary completion
Dec 31, 2026
Study completion Mar 30, 2027
Sponsor
- Lead sponsor
- FUSMobile Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 17, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study involves the use of sound waves to block pain signals caused by osteoarthritis of the knee. The sound waves are tightly focused on a specific area of the nerve. The sound waves cause a break in the nerve which carries pain signals. Sound waves transmit through the skin so there is no need for needles. The procedure takes approximately one hour. The device has been approved in Health Canada and Europe for the treatment of lower back pain. This study is to evaluate the use of the same device for people in Canada who have knee pain related to osteoarthritis.
Conditions
- Osteoarthritis (OA) of the Knee
- Knee Pain Arthritis
- Chronic Knee Pain
Interventions
Neurotomy of the medial sensory articular branchesDevice
Non-invasive thermal ablation of the medial sensory articular branches of the knee joint
Primary outcomes
What the sponsor says the trial is designed to measure.
- A positive clinical outcome will be measured by a 2-point reduction in the Numerical Rating Score (NRS)Time frame: Baseline score will be compared to post procedure intervals at 2 days, 7 days, 1 month, 3 months, and 6 months.
- Safety will be measured by the incidence and severity of treatment-related adverse events.Time frame: Adverse events will be evaluated at baseline and post procedure - 2 days, 7 days, 1 month, 3 months, and 6 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Unika Medical Centre
North York, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.